In a nutshell This review provided the long-term outcomes of the first human trial of the anti-PD-1 drug BMS-936558. It also evaluated whether restarting therapy for cancer recurrences can be effective. Results showed that anti-PD-1 drugs have clinical potential. Some background The PD-1 protein (or "programmed cell death-1" protein)...
Read More
In a nutshell The present study evaluated the effect of Abiraterone acetate (AbAc) on survival and disease progression, when given to patients with metastatic prostate cancer (mPC) that is resistant to hormone therapy (castration-resistant). Some background Prostate cancer (PCa) growth is fueled by male hormones like...
Read More
In a nutshell This paper presents the results of a clinical study which looked at the use of a new drug called Bosutinib (Bosulif) for the treatment of breast cancers diagnosed as being stage III or IV. In patients previously treated with chemotherapy, Bosutinib showed promising efficacy in delaying cancer progression. Some background Locally...
Read More
In a nutshell This study compared the efficacy of Eribulin (Halaven) versus other treatments in women with previously treated stage IV breast cancer. Eribulin extended overall survival more than the other treatment options. Some background Late stage breast cancer offers limited treatment options. At this point in the disease,...
Read More
In a nutshell This report aimed to establish if radiofrequency ablation (RFA) of liver metastases originating from colorectal cancer (CRC) provides any benefits to patients with Stage IV of the disease. Main result: RFA extends progression-free survival by 7 months. Some background RFA is a medical procedure for treating patients with small tumors...
Read More
The present clinical trial evaluated the safety of an immune-based therapy (termed ‘combined immunotherapy’) as an alternative to chemotherapy for the treatment of metastatic (spread with distant metastases) prostate cancer non-responsive to hormonal treatment, or ‘castration-resistant prostate cancer’ (mCRPC). The trial aimed...
Read More
In a nutshell The present study summarized the outcomes of four clinical trials assessing the side-effects reported with sipuleucel-T treatment in patients with prostate cancer. The combined results indicated that this drug is relatively safe with mostly mild to moderate, short-term, and reversible side-effects. Some background As of...
Read More
